NCT06085742View on ClinicalTrials.gov

BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 22, 2023

Primary Completion Date

September 30, 2034

Study Completion Date

September 30, 2034

Conditions
Breast Cancer
Interventions
DRUG

Cyclophosphamide

60mg/m2 PO once a day (21 continuous days)

DRUG

Methotrexate

10mg/m2 PO BID on days 1, 8, and 15

DRUG

Capecitabine

825mg/m2 PO BID on days 1-14

Trial Locations (1)

60612

RECRUITING

University of Illinois, Chicago

All Listed Sponsors
lead

University of Illinois at Chicago

OTHER